Viatris (VTRS) said Thursday it projects a compound annual growth rate for total revenue of 5% to 6% through 2030.

The pharmaceutical firm's long-term financial goals also include an adjusted earnings per share compound annual growth rate between 9% and 10%, alongside over $3 billion in annual free cash flow by the end of the decade, it said.

A recent strategic review outlined roughly $650 million in gross cost reductions across a three-year span, while the company anticipates generating more than $11 billion in available capital for allocation through 2030, Viatris said.

The company also said it plans to launch Meloxicam in the US, and Pitolisant and Effexor in Japan in the near term.